Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.
Assembly Biosciences, Inc. (ASMB) news on Stock Titan centers on the company’s progress in developing small-molecule therapeutics for serious viral diseases. Assembly Bio describes itself as a biotechnology company focused on herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections, and its news flow reflects clinical, scientific and corporate developments across these areas.
Investors following ASMB news can expect regular updates on clinical trial milestones. Recent press releases detail interim Phase 1b results for long-acting HSV helicase-primase inhibitor candidates ABI-5366 and ABI-1179 in participants with recurrent genital herpes, including reported reductions in HSV-2 shedding rates, high viral load shedding and genital lesion rates in certain dosing cohorts. News items also cover Phase 1b data for ABI-4334, a next-generation capsid assembly modulator candidate in chronic HBV infection, and Phase 1a interim data for ABI-6250, an oral HDV entry inhibitor candidate evaluated in healthy participants.
Another key theme in Assembly Bio’s news is its collaboration with Gilead Sciences. Company announcements describe Gilead’s rights to opt in to exclusive licenses for specific programs and report that Gilead has exercised its combined option to license the HSV helicase-primase inhibitor programs ABI-5366 and ABI-1179 for recurrent genital herpes. These items provide context on how the collaboration may influence development responsibilities, potential milestones and royalty structures.
Financial and corporate updates also feature prominently in ASMB news. Quarterly results outline collaboration revenue from Gilead, research and development spending on HSV, HBV and HDV programs, and general and administrative expenses. Additional releases describe equity financings, including an underwritten offering of common stock and warrants and a private placement with Gilead, along with the intended use of proceeds for general corporate purposes.
For investors and observers, the ASMB news feed offers a consolidated view of Assembly Biosciences’ clinical data disclosures, collaboration developments, financing activities and participation in scientific and investor conferences. Bookmarking this page can help track how the company’s antiviral pipeline and partnership with Gilead evolve over time.
Assembly Biosciences (ASMB) reported Q3 2021 financial results, highlighting a net loss of $18.8 million, or $0.41 per share, compared to $3.3 million, or $0.09 per share, in Q3 2020. Revenue from collaborative research significantly declined to $6.3 million from $34.6 million year-over-year, primarily due to the discontinuation of the ABI-H2158 project. R&D expenses decreased to $18.5 million, reflecting the wind-down of the microbiome program. Assembly Bio aims to advance their core inhibitor ABI-4334 into clinical trials in 2022, and they have two ongoing Phase 2 studies involving their lead candidate vebicorvir (VBR).
Assembly Biosciences (Nasdaq: ASMB) announced its participation in the AASLD The Liver Meeting from November 12-15, 2021, featuring significant clinical data on its HBV core inhibitor program. The company will present findings from three studies: one oral presentation and two poster presentations, including a late-breaking poster on the preclinical candidate ABI-4334. The results aim to enhance the understanding of HBV and demonstrate the potential of core inhibitors for treating chronic HBV infection.
Assembly Biosciences (ASMB) and Antios Therapeutics announced a clinical collaboration to assess a triple combination treatment for chronic hepatitis B (HBV). The Phase 2a ANTT201 trial will evaluate the safety and efficacy of Antios’ ATI-2173, Assembly Bio’s vebicorvir (VBR), and tenofovir disoproxil fumarate in ten treatment-naive patients. The study aims to provide a functional cure for HBV, which affects approximately 270 million people globally, offering hope for improved treatment options.
Assembly Biosciences (Nasdaq: ASMB) announced its participation in two upcoming conferences focused on hepatitis B virus (HBV). The Science of HBV Cure Meeting 2021 will feature Dr. William Delaney presenting on novel capsid inhibitors on October 12. Additionally, CEO Dr. John McHutchison will participate in the H.C. Wainwright 2nd Annual HBV Conference on October 13. These engagements highlight Assembly Bio's commitment to advancing therapies for the estimated 270 million people living with HBV worldwide.
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced the grant of stock options to two new employees, allowing the purchase of 16,000 shares at an exercise price of $3.46, the closing price on October 1, 2021. These options have a ten-year term, vesting over four years, and are granted as inducements for accepting employment. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are approved by the independent Compensation Committee. Assembly Bio focuses on developing innovative treatments for hepatitis B virus (HBV).
Assembly Biosciences (ASMB) announced the discontinuation of its ABI-H2158 development after observing elevated alanine transaminase (ALT) levels in a Phase 2 trial, indicating drug-induced hepatotoxicity. Patient safety remains a priority, and the company will focus on advancing ongoing triple combination studies and developing other core inhibitor candidates. The Phase 2 study for ABI-H2158 involved 88 patients, with some suffering significant ALT elevations. The FDA has placed the drug on clinical hold. Assembly Bio aims to extend its cash runway into late 2023 while progressing promising pipeline assets.
Assembly Biosciences, Inc. (Nasdaq: ASMB) has selected a new core inhibitor candidate, ABI-4334, optimized for potency, to advance into clinical development targeting hepatitis B virus (HBV). The company is executing preclinical work with plans to initiate clinical studies in 2022. ABI-4334 shows promising preclinical results, including single-digit nanomolar potency against new virus production and cccDNA formation. The candidate demonstrates pan-genotypic activity, an improved resistance profile, and favorable pharmacokinetics, aiming to offer a finite and curative HBV therapy.
Assembly Biosciences (ASMB) reported its Q2 2021 financial results, highlighting a cash position of $199.1 million. However, revenues plummeted to $0, down from $39.4 million in Q2 2020, due to the termination of its microbiome collaboration with Allergan. R&D expenses decreased to $16.7 million from $23.3 million, while general and administrative costs fell to $6.9 million from $9.5 million. The net loss was $23.6 million, or $0.55 per share, compared to net income of $7.3 million, or $0.21 per share, in the previous year. The company aims to advance its HBV clinical programs.
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced the promotions of Jason Okazaki to Chief Operating Officer and Michael Samar to Chief Financial Officer. Okazaki, with 20 years of business and legal experience, has been with Assembly Bio since 2020, while Samar has over 20 years in finance and operations since joining the company in 2017. CEO John McHutchison praised their contributions toward achieving long-term objectives in developing therapies targeted at hepatitis B virus (HBV). The company aims to provide curative treatments for the 270 million HBV-infected individuals globally.
Assembly Biosciences Appoints Dr. Michael Houghton to Board
Assembly Biosciences, Inc. (Nasdaq: ASMB) has appointed Sir Michael Houghton, PhD, a Nobel Prize-winning virologist, to its board of directors. Dr. Houghton, renowned for discovering the hepatitis C virus, brings over 40 years of drug development experience. His expertise is expected to enhance Assembly Bio's efforts towards finite and curative therapies for hepatitis B virus (HBV), targeting over 250 million individuals globally. CEO John McHutchison emphasized the potential impact of Dr. Houghton’s insights on the company's innovative therapeutic pipeline.